Alpha Cognition Inc.

Market Cap $33.67M
Debt $1.00M
Cash $3.77M
EV $30.90M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Equity	-$2.92M
Growth Stability	1
PB	-11.53
Price/Cash	0.11
Debt/Equity	-0.34
Earnings Growth QoQ	-300%
Market Cap	$33.67M
Assets	$5.03M
Total Debt	$1.00M

Cash	$3.77M
Shares Outstanding	5.93M
EV	30.9M
Working Capital	1.51M
Current Ratio	1.5
Shares Growth 3y	5%
Equity Growth QoQ	110%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The Companys pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Companys ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for traumatic brain injury. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein.

SEC Filings

Direct access to Alpha Cognition Inc. (ACOG) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30

Sector Comparison

How does Alpha Cognition Inc. compare to its competitors?

Not enough data to generate a comparison chart between Alpha Cognition Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Alpha Cognition Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Alpha Cognition Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Alpha Cognition Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	03/2015	TTM
Net Margins	-	-
ROA	-	-
ROE	-	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	03/2015	TTM
Debt over FCF	-	-
Debt over Equity	-	-0.34
Growth Stability	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-0.34)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	03/2015	CAGR 5Y
Revenue YoY growth	-	-
Earnings YoY growth	-	-
Equity YoY growth	-	-
FCF YoY growth	-	-